Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2026)
Arcturus Therapeutics Holdings (ARCT) reported EBITDA Margin of 1308.3% for Q1 2026, down 126039.0% on a YoY basis from N/an in Q1 2025, and down 223.76% quarter-over-quarter from 404.1% in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) EBITDA Margin (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings has reported EBITDA Margin for 9 years, with the latest figure at 1308.3% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 126039.0% year-over-year to 1308.3%; the trailing twelve-month figure through Mar 2026 stood at 143.8% (down 9633.0% YoY), and the FY2025 full-year result was 80.19%, down 2705.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 1308.3%, down from 404.1% in the prior quarter.
- The five-year high for EBITDA Margin was 73.21% in Q4 2022, with the low at 1308.3% in Q1 2026.
- Historically, EBITDA Margin has averaged 228.28% across 5 years, with a median of 70.55% in 2024.
- Annual changes were most pronounced in 2022 — EBITDA Margin surged 264810 bps — and 2026, when it plunged 126039 bps.
- Arcturus Therapeutics Holdings' EBITDA Margin stood at 73.21% in 2022, then plunged by 152 bps to 37.94% in 2023, then slumped by 247 bps to 131.8% in 2024, then tumbled by 207 bps to 404.1% in 2025, then tumbled by 224 bps to 1308.3% in 2026.
- The last three EBITDA Margin figures came in at 1308.3% (Q1 2026), 404.1% (Q4 2025), and 78.41% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - | -1,308.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,308.30% |
| Dec 31, 2025 | -404.10% |
| Sep 30, 2025 | -78.41% |
| Jun 30, 2025 | -32.44% |
| Mar 31, 2025 | -47.91% |
| Dec 31, 2024 | -131.80% |
| Sep 30, 2024 | -16.56% |
| Jun 30, 2024 | -34.53% |
| Mar 31, 2024 | -70.55% |
| Dec 31, 2023 | -37.94% |
| Sep 30, 2023 | -35.94% |
| Jun 30, 2023 | -499.57% |
| Mar 31, 2023 | 63.22% |
| Dec 31, 2022 | 73.21% |
| Sep 30, 2022 | -263.79% |
| Jun 30, 2022 | -79.59% |
| Mar 31, 2022 | -975.76% |
| Dec 31, 2021 | -667.29% |
| Sep 30, 2021 | -2,219.29% |
| Jun 30, 2021 | -2,727.69% |